QIAGEN NV QGEN recently launched its Qiagen Clinical Insight (QCI) bioinformatics platform to facilitate clinical testing labs study genomic variants identified through next-generation sequencing (NGS) data. This indicates the company’s efforts to bolster its footprint in the rapidly evolving global bioinformatics market.
QCI is a comprehensive, bioinformatics content and software platform that can analyze genomic variants available in published biomedical literature, professional association guidelines, public databases and annotations, drug labels and clinical trials. This platform holds immense value in the multi-billion dollar oncology market, as it supports both somatic and hereditary cancer testing.
The platform’s strong software base, secure web application and the company’s private data center jointly allow clinicians to rapidly categorize genomic variants and perform geographical clinical trial matching. This, in turn, aids faster interpretations of gene-based data and consequently expedites the delivery of appropriate treatment for patients.
The QCI platform also offers clinicians access to the Allele Frequency Community – the world's largest repository of ancestral and ethnic diversity data – thus promising a crucial role in genomic clinical trials. Per management, QCI is the latest addition to Qiagen’s portfolio of Sample to Insight solutions that are significant contributors to NGS growth across clinical research and diagnostic lab spaces.
Per reliable resources, accurate and timely extraction of clinically actionable genomic variants from raw sequencing data and then reporting it in a user-friendly way is a daunting task in molecular testing procedures. This latest QCI platform allows clinicians to produce useful, scalable outcomes that address this so-far-unmet bioinformatics challenges.
Clinical labs performing NGS-based tests particularly face time and cost hurdles when transforming genetic information into clinically relevant analyses for physicians. Through its collaboration with leading labs, Qiagen has successfully deployed the QCI platform offering accurate workflow support at a reduced time and cost.
Per management, in bioinformatics and NGS, Qiagen is leaving no stone unturned to expand its portfolio with universal solutions. The company is also preparing for commercialization of the GeneReader NGS workflow in the latter half of 2015.
Moreover, Qiagen is signing new commercialization agreements to strengthen itself in the bioinformatics space. Its latest collaboration with BGI – the world’s largest genomics organization – is one such effort. Under this agreement, BGI will offer Qiagen’s Ingenuity Variant Analysis solution to its sequencing services customers, thus boosting Qiagen’s overall customer base.
The global bioinformatics market accounted for $4.2 billion in 2014 and is poised to reach $13.3 billion by 2020 at a CAGR of 20.9% during 2015–2020 (according to Research and Markets). We believe Qiagen’s positive efforts adequately positions it to capture a larger share of this market, going ahead.
Currently, the stock carries a Zacks Rank #3 (Hold). Some better-ranked med-biomed/generic stocks are Actelion Ltd. ALIOF, Gilead Sciences Inc. GILD and Illumina Inc. ILMN. All the three stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment